Navigation Links
Medarex Announces 2007 Fourth Quarter and Year End Financial Results

share, basic and

diluted $(1.11) $(1.24) $(0.29) $(0.34)

Shares used in computing

basic and diluted

Non-GAAP net loss per

share 126,665 121,126 127,409 124,593

(1) In management's view, the operations of Celldex are not necessarily

indicative of, or directly attributable to, Medarex's continuing

operations. Celldex's operations relate primarily to the research,

development and commercialization of therapeutic vaccines, which is

outside the scope of Medarex's core business operations.

(2) For the twelve and three months ended December 31, 2007, Medarex

incurred $18.6 million and $4.8 million in non-cash stock compensation

expense, of which $8.9 million and $2.1 million is included in

research and development expense and $9.7 million and $2.7 million is

included in general and administrative expenses. Stock compensation

expense includes costs associated with stock awards, including stock

options which were recorded in accordance with the provisions of FAS

123(R). FAS 123(R) requires companies to record stock-based payments

in the financial statements using a fair value method. Medarex adopted

FAS 123(R) on a modified prospective basis beginning on January 1,


In addition to excluding the items described in footnotes 1 and 2 above, items have been excluded based upon management's evaluation (on an individual basis) of both quantitative and qualitative aspects of the item, including, (i) size and nature, (ii) whether it relates to our ongoing business operations, and (iii) whether management expects it to occur as part of our normal business on a regular basis. Those additional items excluded for purposes of determining non-GAAP net loss and non-GAAP net loss per share are acquisition of in-process technol

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Present at the JPMorgan Small/Mid Cap Conference
5. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
6. Grupo Casa Saba Announces Fourth Quarter 2007 Results
7. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
8. Reproductive Medicine Associates of Texas Announces Open House in San Antonio
9. ( Announces Upcoming Interview With Chairman and CEO of flexSCAN, Inc.
10. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
11. Thomson Healthcare Announces Enhancements to Order Sets Solution
Post Your Comments:
(Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT Medical Tracking Systems ... TRACTUS, the world’s first sterile field scanner. , The TRACTUS platform ... FDA’s recent Unique Device Identifier (UDI) Final Rule, which will require manufacturers to ...
(Date:10/9/2015)... ... October 09, 2015 , ... Confidence Plus ... program, a community improvement initiative that involves working with a series of local ... assistance of Confidence Plus Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... welcoming individuals from all walks of life to save money on the high ... of $25 per month per medication, individuals and families can receive their medications ...
(Date:10/9/2015)... ... October 09, 2015 , ... Santa Rosa Consulting and The University of Texas ... to go-live on the Epic platform in March of 2016. Both entities have already ... execute the contract by supporting Scheduling Appointment Conversion and the Go-Live. , “We ...
(Date:10/9/2015)... ... October 09, 2015 , ... Amada Senior Care, premier provider ... office in Maryland – its Bethesda location. Amada franchise partner Steve ... management technology consultant to many of the largest construction firms in the Mid-Atlantic ...
Breaking Medicine News(10 mins):
... Children normally experience flights of fancy, including imaginary friends and ... having hallucinations and delusions which might be the early signs ... whether they had ever seen things or heard voices that ... found that nearly 6 percent may be showing at least ...
... the dawn of a new age in genomics, researcher says ... a Stanford University professor of bioengineering, now has a very ... was the focus of the first completely mapped genome of ... The scan was conducted by a team of Stanford researchers ...
... for the first time that molecules called microRNA can ... The study, led by researchers at the Ohio State ... Richard J. Solove Research Institute, shows that microRNA-155 (miR-155) ... the damage when the wrong bases are paired in ...
... helping the National Oceanic and Atmospheric Administration (NOAA) keep tabs ... satellite images from time to time. NOAA is the lead ... oil spill extent. A semisubmersible drilling platform called the ... Delta experienced a fire and explosion at approximately 11 p.m. ...
... The face and body waxing ... customers daily. Whether it,s a bikini wax or eyebrow shaping for her or a back or ... services for both men and women at affordable prices., , ... (PRWEB) April 27, 2010 -- The face and body waxing specialists, Uni ...
... majority supports expanding insurance, but most say the measure ... 30 (HealthDay News) -- One month after President Barack ... remain divided on the measure, with many people still ... Interactive/HealthDay poll finds. , Supporters and opponents of the ...
Cached Medicine News:
(Date:10/9/2015)... Ansun BioPharma announced a presentation at IDSA,s ... regarding the compassionate use of DAS181 under an emergency ... was co-infected with influenza and parainfluenza (Abstract # 766 ... 2 requirement was reduced and the patient,s respiratory ... off the respirator on day 5. Between day 2 ...
(Date:10/8/2015)... -- Johnson & Johnson (NYSE: JNJ ) today announced ... Sierra Leone of a preventive Ebola ... recruitment is underway, and the first volunteers have received their ... Janssen,s Ebola prime-boost vaccine regimen in a West African country ... Leone,s Kambia district, where some of the country,s ...
(Date:10/8/2015)... 2015  Allergan plc (NYSE: AGN ), a ... hold its R&D Day on November 4, from 11:00 ... 1:00 p.m. PT). The company will also host its ... a.m. ET (6:00 a.m. PT). ... --> Logo - ...
Breaking Medicine Technology:
... Plexus Biomedical Inc. has been granted a new ... to market the first device clinically shown to help ... vaginal delivery are a frequent complication of childbirth and ... U.S. every year. The patented Hem-Avert® Perianal ...
... 2011 GeoVax Labs, Inc. (OTC Bulletin Board: ... Phase 1 clinical trial testing of its HIV/AIDS vaccine products. ... DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like ... The Journal of Infectious Diseases . A PDF ...
Cached Medicine Technology:
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... For physicians looking for a ... advanced communications with electronic storage ... the best of both worlds. ... easy-to-use features of the Atria ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: